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Introduction
Polyarteritis nodosa is a multi-system, necrotizing vasculitis of
medium-sized arteries. In humans, the involvement of the visceral
and renal arteries is characteristic. In the pathogenesis of pol-
yarteritis nodosa, a role of viral antigens is documented for the
hepatitis B virus (HBV)-positive type, which is seen as a distinct
form of polyarteritis nodosa and is treated with anti-viral therapy
[1]. The pathogenesis of the HBV-negative forms of polyarteritis
nodosa is still unknown.
Patients usually present with weakness, malaise, weight loss,
headache, abdominal pain, testicular pain and myalgias. Despite
improvements in the therapy of polyarteritis nodosa, about 10% of
patients still die from fulminant polyarteritis, with a median sur-
vival time of 3 months after diagnosis [2]. In more than 30% of the
patients, hypertension is observed. Cases have been reported with
renin-dependent hypertension. In these cases, hypertension was
believed to be secondary to polyarteritis-associated inflammation
of renal arteries [3–5].
Recently, the cyp1a1ren-2 transgenic rat has been generated
as a transgenic model of renin-dependent hypertension [6]. In
these rats, occasionally, cases have been observed with nodular
infiltration of mesenteric vessels, as is typical for polyarteritis
nodosa (Peters, B. unpublished observations). In cyp1a1ren-2
transgenic rats, the expression of the ren-2 renin transgene is
under the control of the promoter of the cyp1a1 gene, which can
be activated by oral administration of various xenobiotics, includ-
ing the non-toxic aryl hydrocarbon compound indole-3-carbinol
(I3C). Thus, the model permits the induction of renin expression
predominantly in the liver. The administration of I3C results in
dose-dependent elevations of plasma prorenin levels [7]. Various
degrees of hypertension can be induced, ranging from mild to
severe hypertension. Long-term administration of 0.125% I3C
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Polyarteritis nodosa is a necrotizing vasculitis of medium-sized arteries of unknown origin. Hypertension is present in 30% of patients
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mented with a telemetric device to measure blood pressure, developed polyarteritis nodosa within 10 weeks of I3C treatment. I3C alone
or instrumentation alone did not cause polyarteritis nodosa. The angiotensin-converting enzyme inhibitor captopril completely prevented
the development of polyarteritis nodosa, indicating that local angiotensin II generation is a pathogenetic factor in this model. The
renin–angiotensin system can play a primary role in the development of polyarteritis nodosa in rats.
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results in stable chronic hypertension in cyp1a1ren-2 transgenic
rats, with the mean arterial pressures around 170 mmHg. At high
concentrations, I3C induces malignant hypertension within 2 weeks
and animals present with severe hypertensive cardiac and renal
damage [6, 8, 9].
The renin–angiotensin system is an important mediator of vol-
ume and blood pressure homeostasis and also a modulator of
inflammatory processes. Angiotensin II (Ang II) causes contraction
of vascular smooth muscle cells and activates nicotinamide adenine
dinucleotide (phosphate) (NAD(P)H) oxidase, thus enhancing the
production of superoxide anions. Furthermore, Ang II activates p38
mitogen-activated protein kinase, JNK and nuclear factor (NF)-B
[10]. It is therefore conceivable that the activation of the
renin–angiotensin system is not only a consequence of polyarteritis
nodosa but might, in fact, be a causal factor in polyarteritis nodosa.
The present study addresses the following questions: Whether
polyarteritis nodosa can reproducibly be induced in cyp1a1ren-2
transgenic rats? Which conditions promote its development?
Whether the renin–angiotensin system is a primary cause of pol-
yarteritis nodosa?
Materials and methods
Animals
Cyp1a1ren-2 transgenic rats were bred at the University of Greifswald. The
animals were housed in a temperature- and humidity-controlled room with
lights on from 06:00 a.m. to 06:00 p.m. Unless otherwise indicated, the
rats received tap water and standard rat chow (Ssniff, Soest, Germany) 
ad libitum. Body weight was recorded twice weekly, and fluid uptake was
averaged over a 2-day period. All procedures were approved by a govern-
mental committee on animal welfare, the guidelines of which are in accor-
dance with the National Institutes of Health (NIH) Guide for the Care and
Use of Laboratory Animals.
Experimental protocol
Thirty adult male cyp1a1ren-2 transgenic rats were randomly assigned to
the following groups: group ‘Con’ (n  3) remained untreated, group
‘TM’ (n  6) received transmitters only, group ‘I3C’ (n  6) was treated
with 0.125% I3C, group ‘ShamTMI3C’ (n  3) was sham-operated and
received 0.125% I3C, group ‘TMI3C’ (n  6) received transmitters and
was treated with 0.125% I3C and group ‘TMI3CCap’ (n  6) received
transmitters and was treated with 0.125% I3C as well as with the
angiotensin-converting enzyme inhibitor captopril. Radiotelemetric
devices were implanted when the animals were 15–16 weeks old. Body
weight before the operation was 34917 g. Immediately after the
implantation of transmitters or at a corresponding age in animals that did
not receive transmitters, the rats were placed on an experimental diet 
(EF 1/80; Ssniff, Soest, Germany) to which NaCl was added to yield a
final NaCl content of 1.0%. After 2 weeks of recovery from surgery, the
body weight of the operated rats was still lower than the body weight of
the rats without operation (TM: 34213 g, ShamTMI3C: 32910 g,
TMI3C: 3474 g, TMI3CCap: 33512 g, versus control: 
3758 g and I3C: 36921 g). At this time point, the experimental proto-
col was started. I3C (Sigma, Deisenhofen, Germany) was added to the diet
to yield a final concentration (dry weight:dry weight) of 0.125%. The
transgene inducer was given for 10 weeks. Rats in the Con and TM groups
continued to receive the experimental diet without I3C. Rats in the
TMI3CCap group additionally received captopril in the drinking water.
Captopril treatment was started simultaneously with the application of I3C
and also lasted for 10 weeks. The dose of captopril was adjusted so as to
accomplish a blood pressure reduction. The captopril concentration in the
drinking fluid was increased from 2 mg/100 ml at the beginning to 
25 mg/100 ml towards the end of the treatment so as to keep blood pres-
sure in the normotensive range, despite rising prorenin levels throughout
the protocol. Captopril concentration in the drinking fluid was the same
for all rats of the TMI3CCap group at any given time point.
Radiotelemetry
Radiotelemetric devices (TA11PA-C40, DSI-Transoma Medical, St. Paul,
MN, USA) were implanted under ether anaesthesia via an abdominal mid-
line incision under aseptic conditions. The transmitters were fixed within
the upper abdominal cavity [11]. During the recording period, data on arte-
rial pressure, heart rate and locomotor activity were acquired with LabPro
software version 3.11 (DSI-Transoma Medical) at 10-min. intervals.
Telemetric data are given as 24-hrs mean values. In three rats (Sham 
TM  I3C), the transmitters were implanted into the abdominal cavity
without inserting the catheter into the aorta.
Histology
At the end of the experiment, the rats were anaesthetized with ether and
killed, organs were taken and all nodular changes in the vasculature of the
mesentericum were identified. For histological investigations, one half of
the left and right cardiac ventricles, mesenteric vessels, abdominal aorta,
pancreas, kidney and brain were fixed in 4% formalin, embedded in paraf-
fin, sectioned at a thickness of 4 m and stained with haematoxylin and
eosin. Furthermore, sections of the mesenteric vessels were stained with
Elastica van Gieson to identify the arteries. Sections of the kidneys were
also stained with Jones methenamine silver method or acid fuchsin orange
G stain (AFOG) or the periodic acid–Schiff reaction was used. For immuno-
histochemistry, 4-m-thick paraffin slices of the mesenteric vessels were
incubated with anti-CD3 (Dako, Hamburg, Germany) in a 1:50 dilution.
Binding of the primary antibody was visualized using the View DAB
Detection kit (Ventana, Vreden, Germany), according to the manufacturer’s
protocol. Furthermore, the chloracetate esterase reaction was applied on
different sections.
Histological investigations were performed in a blinded fashion by an
investigator who was unaware of the study groups.
Blood sampling and determinations of renin,
prorenin and autoantibodies
On the day before induction and after 3 and 6 weeks, 1.5 ml of ethylenedi-
aminetetraacetic acid (EDTA)-blood were collected from the retro-orbital
plexus under light ether anaesthesia. Plasma active renin (PRC) levels were
determined enzymatically by the capacity of the enzyme to generate
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angiotensin I (Ang I), as described previously [12]. Plasma prorenin levels
were determined after trypsin activation [12]. Serum was diluted 1/100 in
PBS and tested for autoantibodies (anti-neutrophil cytoplasmatic antibod-
ies [ANCA] and anti-nuclear antibodies [ANA]) by indirect immunofluores-
cence. NOVA Lite IFA-ANCA slides (5  6 wells) and -ANA slides (INOVA
Diagnostic, San Diego, CA, USA) were used as antigens and polyclonal
goat-anti-rat IgG-FITC (DIANOVA, Hamburg, Germany) in a dilution of
1/100 was used as the detection antibody.
Statistical analyses
Data are given as means  standard deviation, except for prorenin levels,
which are given as medians. The differences in blood pressure levels 
and renin levels between the groups were evaluated by a one-way ANOVA,
followed by Bonferroni’s all pairwise post-hoc comparisons. For the differ-
ences in weight gain and prorenin levels, ANOVA on ranks (Kruskal–Wallis),
followed by Dunn’s all pairwise post-hoc comparisons, was performed. 
P-values of less than 0.05 were accepted to indicate statistical significance.
All statistical analyses were performed using the SigmaStat software
(SPSS, Inc., Chicago, IL, USA).
Results
Increase of blood pressure by I3C 
and its prevention by captopril
In cyp1a1ren-2 transgenic rats, prorenin-dependent hypertension
was induced. Without I3C treatment, the blood pressure in
cyp1a1ren-2 transgenic rats was in the normal range and was 
stable (TM: 10511 mmHg, the average of 10 weeks; Fig. 1). In
I3C-treated rats (TMI3C), the mean arterial pressure increased
continuously until it reached a plateau of about 170 mm Hg at
week 6 (Fig. 1). The angiotensin-converting enzyme inhibitor cap-
topril prevented partially the I3C-induced increase in the mean
arterial pressure to a mean of 125 mmHg in TMI3CCap rats,
but still it was higher than in the TM group (P  0.05).
Body weight
One clinical criterion for polyarteritis nodosa is weight loss.
During the 10-week protocol, there were no statistically significant
differences in weight gain between the following groups: Con: 18 
3%, TM: 18  7%, I3C: 11  3% and Sham TM  I3C: 12  4%
(n.s.; Fig. 2). In contrast, TM  I3C rats kept loosing weight as a
clinical sign of polyarteritis nodosa (TM  I3C: –15  6%; 
P  0.001 versus all other groups). The difference in the body
weight changes between TMI3C rats and all other groups was
statistically significant already 6 weeks after the start of I3C
 treatment. Captopril prevented the weight loss. The weight gain in
captopril-treated rats was not different from control groups (TM 
I3C  Cap: 18  6%, n.s.; Fig. 2).
Histology
All chronically instrumented rats (TM, TMI3C and TMI3CCap)
showed a granulomatous inflammation with epitheloid
macrophages and multi-nuclear giant cells as well as a deposition
of an amorphous acellular material, characteristic for a foreign
body reaction, at the insertion site of the catheter (Fig. 3A). There
were no differences regarding this reaction between rats with and
without I3C treatment. In addition to these changes, TMI3C rats
clearly showed histological signs resembling classical polyarteri-
tis nodosa, including fibrinoid necrosis of the media, associated
with transmural infiltration of lymphocytes, macrophages and
plasma cells as well as a few neutrophils and eosinophils.
Additionally, prominent perivascular granulation tissues with
haemorrhages and intravascular thrombi were present. This
chronic necrotizing vasculitis was predominantly found in
medium-sized mesenteric arteries, such as the cranial mesenteric
artery and/or celiac artery, with nodules up to 3 mm in diameter
(Fig. 3B). Together with the celiac artery, the arteries of the pancreas
were affected (Fig. 3C). Furthermore, a necrotizing vasculitis in the
testes (not shown) and kidneys (Fig. 3D) of these animals was
observed. Additionally, tubular protein casts and intracytoplas-
matic protein resorption droplets were seen in the kidneys of these
Fig. 1 Effect of captopril treatment on the mean arterial pressure in
cyp1a1ren-2 transgenic rats receiving indole-3-carbinol (I3C). TM: non-
treated rats with transmitter, TMI3C: I3C-treated rats with transmitter
and TMI3CCap: I3C-treated rats with transmitter and captopril; 
n  6 per group. Time 0 marks the start of treatment with I3C and cap-
topril, respectively. *P  0.01 versus TM; §P  0.001 versus TMI3C.
J. Cell. Mol. Med. Vol 14, No 6A, 2010
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Fig. 2 Weight loss in rats with polyarteritis
nodosa and its prevention by captopril. Con:
untreated control rats (n  3), TM: non-
treated rats with transmitter (n  6), TMI3C:
I3C-treated rats with transmitter (n  6),
Sham TMI3C: sham-operated I3C-treated
rats (n  3) and TMI3CCap: I3C-treated
rats with transmitter and captopril (n  6).
Time 0 is the start of treatment with I3C and
captopril and the initial weight of 100%,
respectively. *P  0.05.
Fig. 3 Histological evidence of polyarteritis nodosa in cyp1a1ren-2 transgenic rats. Representative tissue sections of I3C-treated rats with transmitters
(TMI3C) (A) Foreign body reaction at the insertion site of the catheter (haematoxylin and eosin staining). (B) Vasculitis of a mesenteric vessel with
dissection of the arterial wall and intraluminal thrombotic material (haematoxylin and eosin staining). (C) Pancreas: arterial nature of the affected ves-
sel confirmed by Elastica van Gieson staining. (D) Fibrinoid necrosis of the endothelial wall of an intraparenchymal medium-sized renal artery; protein
casts in the tubuli and intratubular protein droplets are stained orange (AFOG staining). Bar  100 m.
1322 © 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
rats, as is typical for hypertension (Fig. 3D). Signs of microscopic
polyarteritis, especially in the glomeruli, were not observed.
Pulmonary and skeletal muscles arteries (hind limb) were not
affected (not shown). The coronary and cerebral arteries showed
thickening of the media as a sign of hypertensive vasculopathy but
no inflammation typical for polyarteritis nodosa (not shown).
Arterial wall infiltration by T cells 
and leucocytes in polyarteritis nodosa in 
cyp1a1ren-2 transgenic rats
Immunohistochemical staining with anti-CD3 monoclonal anti-
body demonstrated the presence of T lymphocytes in the inflam-
matory areas (Fig. 4A) of the mesenteric arteries of TMI3C rats.
Additionally, chloracetate esterase-positive polymorphic leuco-
cytes (Fig. 4B), activated fibroblasts and monocytes as compo-
nents of the inflammation were observed.
Polyarteritis nodosa occurred only in the group of TMI3C
rats (five out of six rats were positive for polyarteritis nodosa; 
Fig. 5C) and was absent in the groups of Con rats (Fig. 5A) and I3C
rats (Fig. 5B). In an independent experiment (groups: Con, I3C:
0.125% and TMI3C, n  5 each), all TMI3C rats, but 
none of the Con or I3C rats, developed polyarteritis nodosa 
(see Supporting Information). Thus, in our model, polyarteritis
nodosa was reproducibly induced by I3C treatment combined with
chronic instrumentation (TMI3C: 10 out of 11 rats).
Telemetric devices are frequently used in hypertension
research. To exclude that polyarteritis nodosa was related to the
device, six rats received a catheter without induction of the
renin–angiotensin system (TM). None of these rats developed
 polyarteritis nodosa (Fig. 5D) nor did the rats that were sham-
operated (Sham TMI3C; Fig. 5E).
To investigate whether the development of polyarteritis nodosa
is influenced by the renin–angiotensin system, six rats received
catheters and were treated with I3C as well as with captopril 
(TMI3CCap). The oral administration of captopril at a final
dose of 25 mg/100 ml of drinking water completely prevented the
development of polyarteritis nodosa (Figs 5F and 6 (bottom)). 
At the same time, five out of six TMI3C rats developed severe
polyarteritis nodosa (Fig. 5C).
Absence of ANCA and ANA
Blood serum was obtained from the rats in all groups at the end
of the experiment. All sera were negative for ANCA and ANA.
Prorenin is necessary but not sufficient 
to induce polyarteritis
To test whether any differences in prorenin levels in I3C-treated
rats may have influenced the development of polyarteritis nodosa,
prorenin levels were compared between the following groups: rats
positive for polyarteritis nodosa (PAN: TMI3C, n  5) versus
non-affected rats without captopril treatment (PAN– : I3C, Sham
TMI3C and one negative TMI3C rat, n  10) and with captopril
treatment [PAN– Cap: TMI3CCap, n  6; at day 21 (Fig. 7A)
and 42 (Fig. 7B)]. Prorenin levels were compared at days 21 and
42 of the experiment, representing time points before and at the
beginning of statistically significant weight loss in these rats. There
was no statistically significant difference in plasma prorenin levels
between PAN and PAN– rats without captopril (day 21: median for
PAN–: 11.3 g Ang I/ml/hr versus PAN: 11.2 g Ang I/ml/hr, n.s.;
day 42: PAN–: 14.9 g Ang I/ml/hr versus PAN: 27.8 g Ang
I/ml/hr, n.s.). Prorenin levels at days 21 and 42 were significantly
higher in captopril-treated rats than in PAN– rats (median for PAN–
Cap day 21: 30.2 g Ang I/ml/hr; day 42: 36.8 g Ang I/ml/hr, 
P  0.05, respectively). Thus, prorenin levels were higher in the
Fig. 4 Identification of CD3-positive cells. (A) Immunohistochemistry of
mesenteric polyarteritis lesions with anti-CD3 (DAB staining). Positively
stained cells are labelled brown. (B) Chloracetate esterase reaction of
mesenteric polyarteritis lesions for the identification of polymorphic leu-
cocytes (red). Bar  100 m.
J. Cell. Mol. Med. Vol 14, No 6A, 2010
1323© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
captopril-treated group than in I3C-treated rats with transmitters
who developed polyarteritis nodosa.
I3C treatment did not increase plasma active renin concentra-
tions within the first 6 weeks (Con: 252  125 ng Ang I/ml/hr, I3C:
113  38 ng Ang I/ml/hr, TM: 199  93 ng Ang I/ml/hr, Sham 
TMI3C: 198  30 ng Ang I/ml/hr and TMI3C: 191  63 ng
Ang I/ml/hr, n.s.). Captopril treatment led to a slight increase in
active renin concentration compared with I3C treatment alone 
(TMI3CCap: 323  133 ng Ang I/ml/hr versus I3C: 113  38
ng Ang I/ml/hr, P  0.05).
Discussion
The pathogenesis of the hepatitis B-negative form of polyarteritis
nodosa is currently unknown. Here, we demonstrate that necrotiz-
ing vasculitis resembling classical polyarteritis nodosa can be
reproducibly induced by the activation of the renin–angiotensin
system under defined conditions (the PAN-cyp1a1ren-2 trans-
genic model). Furthermore, we show that polyarteritis nodosa in
this model can be prevented by the angiotensin-converting
enzyme inhibitor captopril.
Fig. 5 Captopril prevented the development of polyarteritis nodosa. Representative tissue sections (same magnification) of the mesenteric vessels of
cyp1a1ren-2 rats (haematoxylin and eosin staining). (A) control rats, (B) I3C-treated rats (I3C), (C) I3C-treated rats with transmitter (TM  I3C), (D)
transmitter-implanted rats (TM), (E) sham-operated rats treated with I3C (Sham TM  I3C) and (F) co-application of I3C and captopril to transmitter-
implanted rats (TM  I3C  Cap). Bar  250 m.
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In transgenic models of angiotensin-induced end-organ dam-
age such as dTGR (human angiotensin and human renin gene
transgenic) or TGR(mRen2)27, severe phenotypes were
observed with proteinuria, fibrosis of the heart, myocardial
infarction and early death [13–15]. The predominantly affected
vessels are the renal and coronary arteries. With high doses of
I3C, cyp1a1ren-2 transgenic rats develop malignant hyperten-
sion with glomerulosclerosis and cardiac microinfarctions after
2 weeks of induction. Under these conditions, fibrinoid necrosis
of the mesenteric vessels occurred, which was seen as a prema-
ture state of hypertension-induced endangiitis obliterans [6]. In
the present study, lower doses of I3C were applied, leading to
only moderate non-malignant hypertension and thus allowing us
to study the rats for a longer period of time than in the previous
studies. The coronary and cerebral arteries only showed thicken-
ing of the media as a sign of hypertensive vasculopathy. The
mesenteric lesions seen in the present study are typical for 
polyarteritis nodosa rather than for hypertension-induced end-
organ damage. These lesions require several weeks to develop
and may have escaped detection in shorter-lasting studies. As in
the human macroscopic form of polyarteritis nodosa, affected
vessels were medium-sized arteries and the sera were negative
for ANCA and ANA. At present, no information is available, how-
ever, about cryoglobulins, which also are negative in human
macroscopic polyarteritis nodosa.
The activation of the renin–angiotensin system and the sub-
sequent development of arterial hypertension are frequent
sequelae of polyarteritis nodosa. In this context, renin is
believed to be released, because of the vasculitis and a subsequent
Fig. 6 Prorenin levels during the development of polyarteritis nodosa.
Prorenin levels in I3C-treated rats that developed polyarteritis nodosa in
a period of 10 weeks of treatment (PAN) or remained unaffected (PAN–:
without captopril; PAN– Cap: with captopril) at 3 and 6 weeks of treat-
ment. I3C: circles (n  6), ShamTMI3C: crosses (n  3), TMI3C:
 triangles (n  6) and TMI3CCap: diamonds (n  6).
Fig. 7 Prevention of polyarteritis nodosa by captopril. Top: prominent
nodular enlargement of mesenteric vessels (yellow arrow) of an I3C-
treated rat with transmitter. The mesentery is devoid of any fat. Bottom:
macroscopic normal vasculature of an I3C-treated rat with transmitter
(black arrow) treated with captopril.
J. Cell. Mol. Med. Vol 14, No 6A, 2010
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stenosis of the renal arteries [2, 4]. The present study shows
that the activation of the renin–angiotensin system-in addition
to its known role as a sequela of polyarteritis nodosa-may also
act as a causal factor in the pathogenesis of the disease. In our
model, polyarteritis nodosa was preceded by increased plasma
prorenin levels and the activation of local renin–angiotens
in systems.
Prorenin may induce polyarteritis nodosa by increasing Ang I
formation, which subsequently increases Ang II and aldosterone
levels . On the other hand, prorenin has been shown to exert
angiotensin-independent effects by binding to the (pro)renin
receptor [16]. These effects include the activation of ERK1/2 and
activation of promyelotic zinc finger protein (PLZF)/p85-alpha
[17], which promotes proliferation and inhibits apoptosis. Also,
prorenin stimulates transforming growth factor (TGF)-	 [18],
which is a potent pro-inflammatory and pro-fibrotic mediator. In
the present study, polyarteritis nodosa was prevented by capto-
pril. As captopril increases prorenin and active renin levels but
prevents the formation of Ang II, our study excludes
angiotensin-independent effects of prorenin and supports
angiotensin-dependent effects of prorenin in the pathogenesis of
polyarteritis nodosa.
To test if a foreign body reaction to the telemetric device was
involved in the development of polyarteritis in cyp1a1ren-2
transgenic rats, telemetric devices were implanted in the
abdomen without puncturing the aorta. When these rats were
treated with I3C, they developed neither a para-aortal granuloma-
tous inflammation nor polyarteritis nodosa. Further studies are
needed to elucidate the potential roles of inflammation and/or
direct endothelial damage, i.e. induced by malignant hyperten-
sion, in conjunction with increased prorenin levels, for the devel-
opment of polyarteritis nodosa. In any case, our data suggest that
several pathogenic factors acted in concert to cause panarteritis
nodosa in our model. The exact role of each individual factor
remains to be determined. In rat models with an activated
renin–angiotensin system, instrumentation in the abdomen with
injury to the aorta might provide a basis for the development of
necrotizing vasculitis.
Polyarteritis nodosa also develops infrequently in old stroke-
prone spontaneously hypertensive rats (SHRSP). Saito et al.
[19] found that polyarteritis nodosa in SHRSP mesenteric arter-
ies was closely related to systolic blood pressures higher than
200 mmHg, suggesting that hypertension per se or hyperten-
sion-induced increased vascular shear stress may be able to
cause polyarteritis nodosa. However, this model is limited as the
disease develops inconsistently, only in old SHRSP, and the pri-
mary events leading to hypertension as well as to polyarteritis
nodosa in this model are unknown. Thus, at the old age of 
15.5 months, only 60% of SHRSP had polyarteritis nodosa. In
contrast, in the present study, polyarteritis nodosa was present
in 91% of young rats after 10 weeks of I3C treatment. By this
time, the mean arterial blood pressure was increased only to
approximately 170 mmHg. Clinical symptoms such as weight
loss became statistically significant already after 6 weeks of I3C
treatment. In view of the short duration of hypertension and the 
relatively low blood pressure levels achieved, the present study
renders a primary role of hypertension per se in the pathogene-
sis of polyarteritis nodosa unlikely, but a permissive role cannot
be ruled out. In particular, the combination of oscillatory shear-
induced redox signalling with Ang II activation of redox-sensitive
molecules may play a pathophysiological role in vascular injury
and inflammation [20].
Necrotizing vasculitis in rats has been observed under treat-
ment with various vasoactive compounds such as theophylline
[21], endothelin receptor antagonists, fenoldopam [22] and selec-
tive phosphodiesterase type 3 (PDE3) [23] as well as PDE4
inhibitors [24]. These compounds have in common that they can
induce systemic hypotension and it has been proposed that this
may lead to decreased oxygen delivery, necrosis, enhanced
endothelial permeability, protein exudation and immigration of
inflammatory cells [25]. It should be noted that all these compo-
nents also stimulate renin release [26–29]. In view of the present
results, it is conceivable that renin release with the subsequent
elevation of Ang II and aldosterone may have played an important
role in the development of necrotizing vasculitis, induced by the
above-mentioned compounds.
ANG II as well as aldosterone in combination with high-salt
diet can induce oxidative stress and inflammation by multiple
actions on VSMCs, monocytes, macrophages and endothelial
cells [30]. Up-regulation of the local vascular renin–angiotensin–
aldosterone system during monocyte differentiation to macrophages
may amplify monocyte migration into the vessel wall [31].
Recently, it has been demonstrated that T cells possess a func-
tional renin–angiotensin system [32] and are capable of produc-
ing and delivering Ang II to sites of inflammation. In the present
study, vascular lesions were infiltrated with polymorphic leuco-
cytes and T cells. As Ang II induces the recruitment of inflamma-
tory cells [33] and promotes the secretion of the chemokine
CCL5/RANTES by natural killer (NK) and T cells [34], overexpres-
sion of prorenin in an already pro-inflammatory status might
induce a vicious circle, which results in massive T-cell infiltration
of the vascular tissue.
Perspectives
In the present model of cyp1a1ren-2 transgenic rat vascular
lesions, resembling classical polyarteritis nodosa, can be induced
under defined conditions by only moderately activating the
renin–angiotensin system. Furthermore, the development of pol-
yarteritis nodosa can be prevented by an angiotensin-converting
enzyme inhibitor. This model now allows us to investigate the
causal factors and molecular mechanisms of the inflammatory
processes that induce, maintain or aggravate the disease in a well-
controlled manner.
Our findings may also have implications for therapy. The fact
that captopril was able to prevent polyarteritis nodosa suggests
that angiotensin-converting enzyme inhibitors may have benefits
beyond blood pressure lowering in hypertensive patients with pol-
yarteritis nodosa.
1326 © 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Acknowledgements
We thank Doreen Nierath, Brigitte Sturm and Anke Wolter for excellent
technical assistance and Barbara M. Broeker and Monika Ehlers for helpful
discussion. The study was supported by a grant from the Federal Ministry
of Education and Research (BMBF/NBL3; FKZ:01ZZ0403). John J. Mullins
is the recipient of a Wellcome Trust Principal Research Fellowship.
Supporting Information
Additional Supporting Information may be available for this article
online:
Fig. S1 Weight loss in rats with polyarteritis nodosa. White cir-
cles: untreated control rats, black circles: I3C-treated rats and
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sections of mesenteric vessels of transmitter-implanted rats with
I3C treatment. Vasculitis and perivasculitis of a mesenterial artery
branch (A). The arterial nature of the vessel was confirmed by
Elastica van Gieson stain (B). Segmental fibrinoid necrosis with
thrombosis typical for panarteritis nodosa (C). Arterial vessel with
subsided inflammation and fibrous obliteration of the lumen (D).
(A) and (C) Haematoxylin and eosin stain; (B) and (D) Elastica van
Gieson stain. Bar  400 m.
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